Type of information: Series B financing round
Company: Exocobio (Republic of Korea)
Investors: Seven Tree Equity Partners (Republic of Korea) CSQUARED Global Asset Management (Republic of Korea) TS Investment Partners (Dubai) K2 Investment, Intervest (Republic of Korea) KDB Capital (Republic of Korea) Atinum Investment (Republic of Korea) GU Equity Partners (Republic of Korea) QUANTUM Ventures Korea (Republic of Korea) Platinum technology Investment (Republic of Korea)
Amount: $27 million
Funding type: series B financing round
- Exocobio will use this funding to set up GMP-compliant exosome manufacturing facilities to produce exosome pharmaceuticals, to attract high quality talents, and to secure additional business opportunities for commercialisation in cosmetics industry. Recently, the company published a scientific paper in the journal of Stem Cell Research and Therapy that stem cell-derived exosomes can dramatically improve atopic dermatitis and inhibit a variety of inflammatory targets, which is the world's first.
- • On September 12, 2018, ExoCoBio announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
- Since it was established in January 2017, ExoCoBio has raised about $46 million accumulatively including series A round in April 2017 of $11 million.
Therapeutic area: Autoimmune diseases - Dermatological diseases